Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder
Condition(s):Attention-deficit Hyperactivity Disorder (ADHD)Last Updated:December 23, 2016Completed